Data as of Mar 07
| -0.21 / -8.05%|
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the developing and manufacturing monoclonal antibody therapeutics for the treatment of cancer and infectious diseases. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent cotara. It has in house cGMP manufacturing capabilities through its wholly owned Subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers. The company operates through two reportable segments; Peregrine and Avid. The Peregrine segment engages in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases. The Avid segment provides contract manufacturing services for peregrine and outside customers on a fee-for-service basis. Peregrine Pharmaceuticals was founded on June 3, 1981 and is headquartered in Tustin, CA.
|Steven W. King||President, Chief Executive Officer & Director|
|Paul J. Lytle||Chief Financial Officer|
|Joseph S. Shan||Vice President-Clinical & Regulatory Affairs|
|Mark R. Ziebell||Secretary, Vice President & General Counsel|
|Shelley P. M. Fussey||Vice President-Intellectual Property|